Immune-vascular cross-talk underpins the rationale for using bevacizumab, an anti-VEGFA monoclonal antibody that normalizes tumor vasculature, in conjunction with immune checkpoint inhibitors in advanced unresectable HCC.5 Here, VEGFA is linked to hepatocellular carcinoma.